461 related articles for article (PubMed ID: 20580849)
1. NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.
Alyea EP; DeAngelo DJ; Moldrem J; Pagel JM; Przepiorka D; Sadelin M; Young JW; Giralt S; Bishop M; Riddell S
Biol Blood Marrow Transplant; 2010 Aug; 16(8):1037-69. PubMed ID: 20580849
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.
Pavletic SZ; Kumar S; Mohty M; de Lima M; Foran JM; Pasquini M; Zhang MJ; Giralt S; Bishop MR; Weisdorf D
Biol Blood Marrow Transplant; 2010 Jul; 16(7):871-90. PubMed ID: 20399876
[TBL] [Abstract][Full Text] [Related]
4. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.
de Lima M; Porter DL; Battiwalla M; Bishop MR; Giralt SA; Hardy NM; Kröger N; Wayne AS; Schmid C
Biol Blood Marrow Transplant; 2014 Jan; 20(1):4-13. PubMed ID: 24018392
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
6. NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.
Miller JS; Warren EH; van den Brink MR; Ritz J; Shlomchik WD; Murphy WJ; Barrett AJ; Kolb HJ; Giralt S; Bishop MR; Blazar BR; Falkenburg JH
Biol Blood Marrow Transplant; 2010 May; 16(5):565-86. PubMed ID: 20152921
[TBL] [Abstract][Full Text] [Related]
7. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science.
Cairo MS; Jordan CT; Maley CC; Chao C; Melnick A; Armstrong SA; Shlomchik W; Molldrem J; Ferrone S; Mackall C; Zitvogel L; Bishop MR; Giralt SA; June CH
Biol Blood Marrow Transplant; 2010 Jun; 16(6):709-28. PubMed ID: 20227509
[TBL] [Abstract][Full Text] [Related]
8. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
[TBL] [Abstract][Full Text] [Related]
9. Non-myeloablative transplants for malignant disease.
Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
[TBL] [Abstract][Full Text] [Related]
10. Relapse after allogeneic hematopoietic cell therapy.
van den Brink MR; Porter DL; Giralt S; Lu SX; Jenq RR; Hanash A; Bishop MR
Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S138-45. PubMed ID: 19857588
[TBL] [Abstract][Full Text] [Related]
11. Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse.
Yakoub-Agha I; Saule P; Magro L; Cracco P; Duhamel A; Coiteux V; Bruno B; Dufossé F; Jouet JP; Dessaint JP; Labalette M
Biol Blood Marrow Transplant; 2009 Apr; 15(4):496-504. PubMed ID: 19285638
[TBL] [Abstract][Full Text] [Related]
12. Adoptive Immunotherapies After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies.
Xiong Y; Bensoussan D; Decot V
Transfus Med Rev; 2015 Oct; 29(4):259-67. PubMed ID: 26282736
[TBL] [Abstract][Full Text] [Related]
13. Overview of Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies.
Singh N; Loren AW
Clin Chest Med; 2017 Dec; 38(4):575-593. PubMed ID: 29128011
[TBL] [Abstract][Full Text] [Related]
14. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
15. The allogeneic HLA-DP-restricted T-cell repertoire provoked by allogeneic dendritic cells contains T cells that show restricted recognition of hematopoietic cells including primary malignant cells.
Laghmouchi A; Hoogstraten C; van Balen P; Falkenburg JHF; Jedema I
Haematologica; 2019 Jan; 104(1):197-206. PubMed ID: 30237261
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
[TBL] [Abstract][Full Text] [Related]
18. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Porter DL; Alyea EP; Antin JH; DeLima M; Estey E; Falkenburg JH; Hardy N; Kroeger N; Leis J; Levine J; Maloney DG; Peggs K; Rowe JM; Wayne AS; Giralt S; Bishop MR; van Besien K
Biol Blood Marrow Transplant; 2010 Nov; 16(11):1467-503. PubMed ID: 20699125
[TBL] [Abstract][Full Text] [Related]
19. Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease.
Burroughs L; Storb R
Curr Opin Hematol; 2005 Jan; 12(1):45-54. PubMed ID: 15604891
[TBL] [Abstract][Full Text] [Related]
20. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
